vs
MKS INC（MKSI）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
MKS INC的季度营收约是Royalty Pharma plc的1.7倍（$1.0B vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs 10.3%，领先24.1%），MKS INC同比增速更快（10.6% vs 4.8%），过去两年MKS INC的营收复合增速更高（9.1% vs 4.6%）
MKS Inc原是跨国独立软件供应商，业务覆盖应用生命周期管理（ALM）及系统管理两大领域，2011年5月31日被参数技术公司（PTC, Inc.）收购，目前为PTC旗下子公司。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
MKSI vs RPRX — 直观对比
营收规模更大
MKSI
是对方的1.7倍
$622.0M
营收增速更快
MKSI
高出5.8%
4.8%
净利率更高
RPRX
高出24.1%
10.3%
两年增速更快
MKSI
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $622.0M |
| 净利润 | $107.0M | $214.2M |
| 毛利率 | 46.3% | — |
| 营业利润率 | 13.9% | 62.4% |
| 净利率 | 10.3% | 34.4% |
| 营收同比 | 10.6% | 4.8% |
| 净利润同比 | 18.9% | 2.9% |
| 每股收益（稀释后） | $1.58 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MKSIRPRX
| Q4 25 | $1.0B | $622.0M | ||
| Q3 25 | $988.0M | $609.3M | ||
| Q2 25 | $973.0M | $578.7M | ||
| Q1 25 | $936.0M | $568.2M | ||
| Q4 24 | $935.0M | $593.6M | ||
| Q3 24 | $896.0M | $564.7M | ||
| Q2 24 | $887.0M | $537.3M | ||
| Q1 24 | $868.0M | $568.0M |
净利润MKSIRPRX
| Q4 25 | $107.0M | $214.2M | ||
| Q3 25 | $74.0M | $288.2M | ||
| Q2 25 | $62.0M | $30.2M | ||
| Q1 25 | $52.0M | $238.3M | ||
| Q4 24 | $90.0M | $208.2M | ||
| Q3 24 | $62.0M | $544.0M | ||
| Q2 24 | $23.0M | $102.0M | ||
| Q1 24 | $15.0M | $4.8M |
毛利率MKSIRPRX
| Q4 25 | 46.3% | — | ||
| Q3 25 | 46.7% | — | ||
| Q2 25 | 46.6% | — | ||
| Q1 25 | 47.4% | — | ||
| Q4 24 | 47.3% | — | ||
| Q3 24 | 48.2% | — | ||
| Q2 24 | 47.2% | — | ||
| Q1 24 | 47.8% | — |
营业利润率MKSIRPRX
| Q4 25 | 13.9% | 62.4% | ||
| Q3 25 | 14.0% | 70.1% | ||
| Q2 25 | 13.9% | 36.3% | ||
| Q1 25 | 11.9% | 94.0% | ||
| Q4 24 | 14.7% | 60.9% | ||
| Q3 24 | 14.3% | — | ||
| Q2 24 | 14.3% | 50.2% | ||
| Q1 24 | 12.2% | -13.0% |
净利率MKSIRPRX
| Q4 25 | 10.3% | 34.4% | ||
| Q3 25 | 7.5% | 47.3% | ||
| Q2 25 | 6.4% | 5.2% | ||
| Q1 25 | 5.6% | 41.9% | ||
| Q4 24 | 9.6% | 35.1% | ||
| Q3 24 | 6.9% | 96.3% | ||
| Q2 24 | 2.6% | 19.0% | ||
| Q1 24 | 1.7% | 0.8% |
每股收益（稀释后）MKSIRPRX
| Q4 25 | $1.58 | $0.49 | ||
| Q3 25 | $1.10 | $0.67 | ||
| Q2 25 | $0.92 | $0.07 | ||
| Q1 25 | $0.77 | $0.55 | ||
| Q4 24 | $1.34 | $0.46 | ||
| Q3 24 | $0.92 | $1.21 | ||
| Q2 24 | $0.33 | $0.23 | ||
| Q1 24 | $0.22 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $418.0M | $618.7M |
| 总债务越低越好 | $4.2B | $9.0B |
| 股东权益账面价值 | $2.7B | $9.7B |
| 总资产 | $8.8B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.53× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资MKSIRPRX
| Q4 25 | $418.0M | $618.7M | ||
| Q3 25 | $413.0M | $938.9M | ||
| Q2 25 | $498.0M | $631.9M | ||
| Q1 25 | $407.0M | $1.1B | ||
| Q4 24 | $420.0M | $929.0M | ||
| Q3 24 | $439.0M | $950.1M | ||
| Q2 24 | $506.0M | $1.8B | ||
| Q1 24 | $1.0M | $843.0M |
总债务MKSIRPRX
| Q4 25 | $4.2B | $9.0B | ||
| Q3 25 | $4.3B | $8.9B | ||
| Q2 25 | $4.4B | $8.0B | ||
| Q1 25 | $4.4B | $7.6B | ||
| Q4 24 | $4.5B | $7.6B | ||
| Q3 24 | $4.8B | $7.6B | ||
| Q2 24 | $4.8B | $7.6B | ||
| Q1 24 | $4.7B | $6.1B |
股东权益MKSIRPRX
| Q4 25 | $2.7B | $9.7B | ||
| Q3 25 | $2.6B | $9.6B | ||
| Q2 25 | $2.6B | $9.5B | ||
| Q1 25 | $2.4B | $9.8B | ||
| Q4 24 | $2.3B | $10.3B | ||
| Q3 24 | $2.4B | $10.3B | ||
| Q2 24 | $2.2B | $9.8B | ||
| Q1 24 | $2.4B | $9.9B |
总资产MKSIRPRX
| Q4 25 | $8.8B | $19.6B | ||
| Q3 25 | $8.8B | $19.3B | ||
| Q2 25 | $8.8B | $18.3B | ||
| Q1 25 | $8.6B | $17.6B | ||
| Q4 24 | $8.6B | $18.2B | ||
| Q3 24 | $9.0B | $18.0B | ||
| Q2 24 | $8.9B | $17.7B | ||
| Q1 24 | $8.9B | $16.1B |
负债/权益比MKSIRPRX
| Q4 25 | 1.53× | 0.92× | ||
| Q3 25 | 1.64× | 0.93× | ||
| Q2 25 | 1.71× | 0.84× | ||
| Q1 25 | 1.87× | 0.78× | ||
| Q4 24 | 1.93× | 0.74× | ||
| Q3 24 | 1.98× | 0.74× | ||
| Q2 24 | 2.16× | 0.78× | ||
| Q1 24 | 1.94× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $142.0M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $92.0M | — |
| 自由现金流率自由现金流/营收 | 8.9% | — |
| 资本支出强度资本支出/营收 | 4.8% | — |
| 现金转化率经营现金流/净利润 | 1.33× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $497.0M | — |
8季度趋势，按日历期对齐
经营现金流MKSIRPRX
| Q4 25 | $142.0M | $827.1M | ||
| Q3 25 | $197.0M | $702.6M | ||
| Q2 25 | $165.0M | $364.0M | ||
| Q1 25 | $141.0M | $596.1M | ||
| Q4 24 | $176.0M | $742.5M | ||
| Q3 24 | $163.0M | $703.6M | ||
| Q2 24 | $122.0M | $658.2M | ||
| Q1 24 | $67.0M | $664.6M |
自由现金流MKSIRPRX
| Q4 25 | $92.0M | — | ||
| Q3 25 | $146.0M | — | ||
| Q2 25 | $136.0M | — | ||
| Q1 25 | $123.0M | — | ||
| Q4 24 | $125.0M | — | ||
| Q3 24 | $141.0M | — | ||
| Q2 24 | $95.0M | — | ||
| Q1 24 | $49.0M | — |
自由现金流率MKSIRPRX
| Q4 25 | 8.9% | — | ||
| Q3 25 | 14.8% | — | ||
| Q2 25 | 14.0% | — | ||
| Q1 25 | 13.1% | — | ||
| Q4 24 | 13.4% | — | ||
| Q3 24 | 15.7% | — | ||
| Q2 24 | 10.7% | — | ||
| Q1 24 | 5.6% | — |
资本支出强度MKSIRPRX
| Q4 25 | 4.8% | — | ||
| Q3 25 | 5.2% | — | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 2.1% | — |
现金转化率MKSIRPRX
| Q4 25 | 1.33× | 3.86× | ||
| Q3 25 | 2.66× | 2.44× | ||
| Q2 25 | 2.66× | 12.06× | ||
| Q1 25 | 2.71× | 2.50× | ||
| Q4 24 | 1.96× | 3.57× | ||
| Q3 24 | 2.63× | 1.29× | ||
| Q2 24 | 5.30× | 6.45× | ||
| Q1 24 | 4.47× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MKSI
| Electronics And Packaging | $303.0M | 29% |
| Specialty Industrial | $295.0M | 29% |
| Photonics Solutions Division | $274.0M | 26% |
| Services | $125.0M | 12% |
| Other | $37.0M | 4% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
